David Evans logo

David Evans

Oceania, New South Wales, Australia, Sydney

Description

David is the inventor/product designer and owner of Tyson and has an extensive background in the locking solutions market with over 20 years...

Investor Profile

David Evans has made 2 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series C (50%)
  • Series Unknown (50%)

Country Focus

  • United Kingdom (100%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Genetics
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does David Evans frequently co-invest with?

Wren Capital
Europe, England, United Kingdom, London
Co-Investments: 1
Molten Ventures
Europe, England, United Kingdom, London
Co-Investments: 2
MVM Life Science Partners
Europe, England, United Kingdom, London
Co-Investments: 2
PI
North America, Georgia, United States, Germany
Co-Investments: 2
Roche Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 2
University of Cambridge Enterprise
Europe, Cambridgeshire, United Kingdom, Cambridge
Co-Investments: 1
Calculus Capital
Europe, England, United Kingdom, London
Co-Investments: 1
Parkwalk Advisors
Europe, England, United Kingdom, London
Co-Investments: 1

Which angels does David Evans often collaborate with?

DC
Europe, Cambridgeshire, United Kingdom, Cambridge
Shared Deals: 1
PC
Europe, England, United Kingdom, London
Shared Deals: 1
JM
North America, Massachusetts, United States, Cambridge
Shared Deals: 2

What are some of recent deals done by David Evans?

Horizon Discovery

Cambridge, Cambridgeshire, United Kingdom

Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.

BiopharmaBiotechnologyGeneticsHealth Diagnostics
Series UnknownJun 3, 2013
Amount Raised: $10,559,533
Horizon Discovery

Cambridge, Cambridgeshire, United Kingdom

Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.

BiopharmaBiotechnologyGeneticsHealth Diagnostics
Series CSep 13, 2011
Amount Raised: $17,853,644